Compass Therapeutics (CMPX) Total Liabilities (2023 - 2025)
Historic Total Liabilities for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $21.6 million.
- Compass Therapeutics' Total Liabilities rose 10130.2% to $21.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.6 million, marking a year-over-year increase of 10130.2%. This contributed to the annual value of $15.2 million for FY2024, which is 8195.99% up from last year.
- Per Compass Therapeutics' latest filing, its Total Liabilities stood at $21.6 million for Q3 2025, which was up 10130.2% from $23.5 million recorded in Q2 2025.
- Compass Therapeutics' 5-year Total Liabilities high stood at $23.5 million for Q2 2025, and its period low was $4.1 million during Q1 2024.
- Over the past 3 years, Compass Therapeutics' median Total Liabilities value was $10.9 million (recorded in 2023), while the average stood at $13.4 million.
- As far as peak fluctuations go, Compass Therapeutics' Total Liabilities plummeted by 6788.36% in 2024, and later surged by 41866.73% in 2025.
- Quarter analysis of 3 years shows Compass Therapeutics' Total Liabilities stood at $8.3 million in 2023, then surged by 81.96% to $15.2 million in 2024, then skyrocketed by 42.69% to $21.6 million in 2025.
- Its last three reported values are $21.6 million in Q3 2025, $23.5 million for Q2 2025, and $21.2 million during Q1 2025.